Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00654030 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Edward Hirschowitz.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00654030: Completed Phase 2 study, sponsored by Edward Hirschowitz.
NCT00654030 is a Phase 2 study that has completed, run by Edward Hirschowitz. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00654030, a Phase 2 study, has completed, sponsored by Edward Hirschowitz.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Rationale: Vaccines made from allogeneic tumor cells may help the body build an effective immune response to kill tumor cells. The Purpose of this study is to evaluate the effects of a lung cancer vaccine in patients with Stage I or Stage II Non-Small Cell Lung Cancer (NSCLC) after completion of initial definitive therapies.
Interventions
- DRUG 1650-G Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00654030
The ClinicalTrials.gov registry entry for NCT00654030 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edward Hirschowitz, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 1650-G Vaccine is the first listed.
NCT00654030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00654030 about?
NCT00654030 is a clinical study titled "Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer". Rationale: Vaccines made from allogeneic tumor cells may help the body build an effective immune response to kill tumor cells. The Purpose of this study is to evaluate the effects of a lung cancer vaccine in patients with Stage I or Stage II Non-Small Cell Lung Cancer (NSCLC) after completion of in...
What is the current status of trial NCT00654030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2006-10. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00654030?
The interventions under investigation include: 1650-G Vaccine (DRUG).
Who is sponsoring clinical trial NCT00654030?
This trial is sponsored by Edward Hirschowitz, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.